- Home
- MURA
MURA
Mural Oncology plc
as 04-18-2025 1:40pm EST
Stocks
| Founded: | 2013 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $13.00 | AVG Volume (30 days): | 14.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $4.74 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 34.35% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Mural Oncology plc (MURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Loew Caroline | MURA | Chief Executive Officer | Mar 3 '25 | Sell | $3.36 | 4,313 | $14,491.68 | 305,590 | |
| Keson-Brookes Maiken | MURA | See Remarks | Mar 3 '25 | Sell | $3.41 | 2,731 | $9,308.37 | 75,033 | |
| Goodman Vicki L | MURA | Chief Medical Officer | Feb 24 '25 | Sell | $3.89 | 13,186 | $51,293.54 | 54,763 |
Latest Mural Oncology plc News
MURA Breaking Stock News: Dive into MURA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Mural Oncology Announces Plans to Explore Strategic Alternatives
GlobeNewswire
25 days ago
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
GlobeNewswire
a month ago
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
GlobeNewswire
2 months ago
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Simply Wall St.
2 months ago
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully
GlobeNewswire
3 months ago
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
GlobeNewswire
5 months ago
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
5 months ago
Raymond James Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
Compare MURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MURA Mural Oncology plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.